Summary Points
- China tightened biotech ownership-transfer rules across five technologies, while licensing deals remain exempt.
- China dominates licensing deals, while U.S. companies account for 91% of M&A transactions.
- Disc Medicine’s Phase 3 trial met endpoints, reduced PPIX, increased light exposure, reviving approval prospects.
- Veradermics’ hair-loss candidate succeeded in Phase 3; ESMO previews ADC, vaccine, and ivonescimab updates.
China tightens control as deals keep moving
China has tightened rules on transferring ownership of five types of biotechnology, including cell and gene therapies. The move signals Beijing’s ambition to expand its influence in global drug development. However, licensing deals are exempt, so many cross-border partnerships can continue.
China is drawing most licensing activity, while U.S. companies are driving acquisitions. U.S.-based firms account for 91% of M&A deals so far this year. The split shows how influence in biotech can grow through different routes.
Disc and Veradermics post late-stage gains
Disc Medicine has a chance to seek approval again for bitopertin, its treatment for erythropoietic protoporphyria, a rare condition that can cause severe pain in sunlight. The FDA rejected the drug in February. Now, a Phase 3 trial met its primary and secondary goals: Patients had lower levels of a disease-linked biomarker and spent more time in the light. For patients, that could mean greater freedom outdoors.
Veradermics also reported positive Phase 3 results. Its oral hair-loss candidate improved hair growth in men, bringing the company closer to an FDA application. The findings are encouraging, though the treatment’s eventual availability and benefits will depend on regulatory review.
ESMO puts new cancer approaches in view
At the upcoming European Society for Medical Oncology Congress in Spain, antibody-drug conjugates are expected to draw attention. Merck and Kelun-Biotech plan to share fuller data on sac-TMT. Merck and Moderna will present detailed results for a personalized mRNA vaccine, while Summit Therapeutics and Akeso will offer more data on ivonescimab.
Together, these updates reflect a broad push toward more targeted cancer care. The promise is meaningful, but trial results still need to show how well treatments work and whether patients can access them.
Continue Your Tech Journey
Explore the future of technology with our detailed insights on Artificial Intelligence.
Learn more about cutting-edge innovations supported by the National Science Foundation (NSF).
Sci-BioV1
